The effect of silymarin on Alzheimer’s diseases
Phase 4
Completed
- Conditions
- Alzheimer disease.Alzheimer's disease
- Registration Number
- IRCT20131219015870N3
- Lead Sponsor
- Faculty of Pharmaceutical Sciences, Islamic Azad University of Medical Sciences, Tehran
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
Patients who diagnosed with brain imaging and biochemical tests, Alzheimer's by a neurologist
Exclusion Criteria
epilepsy
heart failure
CKD
hypothyroidism
vitamon b 12 deficiency
psychiatric desease
stroke
brain tumor
hydrocephaly
encephalitis
pragnancy
excerbation of symptoms when patiants want to start silymarin
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Score of cognitive function in Mini Mental State Examination. Timepoint: At the beginning of the study (before the intervention) and 3 months later. Method of measurement: Mini Mental State Examination.;Serum levels of TNF-a inflammatory factor. Timepoint: At the beginning of the study (before the intervention) and 3 months later. Method of measurement: ELISA.;Serum levels of IL-1ß inflammatory factor. Timepoint: At the beginning of the study (before the intervention) and 3 months later. Method of measurement: ELISA.
- Secondary Outcome Measures
Name Time Method